LYA-Immuno 2 Drug Detail
Label-linked therapy, administration, access, and operational details for provider teams.
NDC: 00000-202-11
Route: Subcutaneous
HCPCS: J3590 (payer-specific temporary mapping)
REMS: No
Clinical Profile
Core facts providers need during therapy onboarding and maintenance.
Provider Tools
Common resources used by office and infusion teams.
Monitoring and Administration Workflow
Operational checkpoints used across provider, nursing, and reimbursement staff.
Contraindications
- Serious active infection
- Known severe hypersensitivity to formulation components
Administration Notes
- Starter dose week 0 and week 2, then every 4 weeks
- Rotate injection sites; avoid bruised or scarred tissue
- Caregiver self-injection training required before home administration
Monitoring Matrix
Baseline
Required: Infection screening panel
Owner: Provider
Quarterly
Required: Disease activity score capture
Owner: Provider + MA
Flare
Required: Document rescue therapy and response
Owner: Provider
Distribution and Access
Supply, coding, and payer preparation details.
Dispensing model
Specialty pharmacy dispense
Refill cadence
28-day supply
Patient onboarding
Nurse educator within 48 hours
Payer Readiness
Evidence package components frequently requested for initial authorization.
Step therapy completion
Recommended evidence: Medication claims history
Specialist attestation
Recommended evidence: Signed provider statement
Disease severity documentation
Recommended evidence: Latest progress note
Interaction Watchouts
- Avoid live vaccines during active treatment
- Review concomitant biologics for duplication risk
Capture Local Notes
Add site-specific details that are not in national references.
Add Drug Detail Note
Capture local administration, coverage, or logistics notes.
Add Access Escalation
Log payer obstacle details and escalation owner for this therapy.